Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Top Trends in Life Sciences Consulting: Innovations Shaping the Future

Nov 15, 2025

Introduction to Life Sciences Consulting Trends

The life sciences sector is experiencing a transformative era, driven by rapid technological advancements and evolving market demands. Life sciences consulting firms are at the forefront, guiding companies through complex challenges and opportunities. In this post, we explore the top trends shaping the future of life sciences consulting.

Embracing Digital Transformation

Digital transformation is revolutionizing the life sciences industry. Companies are increasingly adopting digital tools to enhance research, development, and operational efficiency. Consultants are crucial in implementing technologies like artificial intelligence (AI) and machine learning (ML) to streamline processes and improve decision-making.

digital transformation

Focus on Personalized Medicine

Personalized medicine is shifting the healthcare landscape by tailoring treatments to individual patient profiles. Life sciences consultants are helping organizations integrate genetic and genomic data into their product development pipelines. This trend promises more effective and targeted therapies, improving patient outcomes.

Consultants play a vital role in navigating regulatory challenges associated with personalized medicine, ensuring compliance while fostering innovation.

Advancements in Biopharmaceuticals

Biopharmaceuticals are gaining traction due to their potential to treat previously untreatable conditions. Consultants are helping companies develop biologics and biosimilars, providing expertise in formulation, clinical trials, and commercialization strategies.

biopharmaceuticals

The focus is on accelerating time-to-market while ensuring safety and efficacy, crucial for maintaining competitive advantage in a rapidly evolving market.

Data-Driven Decision Making

Data analytics is becoming indispensable in the life sciences sector. Consultants are leveraging big data to drive insights and innovation. By harnessing patient data, market trends, and clinical trial results, companies can make informed decisions that enhance product development and market positioning.

  • Improved patient outcomes
  • Optimized clinical trials
  • Enhanced market strategies

Sustainability and Environmental Impact

As environmental concerns rise, the life sciences industry is focusing on sustainability. Consultants assist companies in adopting eco-friendly practices, reducing waste, and minimizing carbon footprints. This trend not only supports environmental goals but also aligns with consumer preferences for sustainable products.

sustainability life sciences

Conclusion: The Future of Life Sciences Consulting

The life sciences consulting landscape is evolving rapidly, driven by technological innovations and changing market dynamics. By staying ahead of these trends, consultants can provide invaluable support to organizations navigating this complex and exciting field. The future promises continued growth and innovation, with consultants playing a pivotal role in shaping the industry.